



Deciphera announces appointment of John de Groot, MD to its Scientific Advisory Board

August 5, 2013

Deciphera is pleased to announce the appointment of John de Groot, M.D. to its Scientific Advisory Board. Dr. de Groot brings critical expertise to Deciphera's SAB in the areas of translational glioma research, mechanisms of resistance to current glioma therapies, and the conduct of clinical trials evaluating novel therapeutics in patients with glioblastoma.

John de Groot, M.D. is a translational and clinical neuro-oncologist in the Department of Neuro-Oncology at the University of Texas – MD Anderson Cancer Center in Houston, Texas whose research focuses on the field of glioma angiogenesis and molecularly targeted therapy. Dr. de Groot is the PI of multiple clinical trials involving novel agents being tested in patients with glioblastoma. His research focuses on mechanisms of resistance, biomarker development, and the identification of novel therapeutic approaches to overcome resistance to antiangiogenic therapy. Other areas of research involve prospective molecular profiling of patient tumors and the identification of subgroups of glioma with sensitivity to specific molecularly targeted agents. A broad background in both clinical and laboratory-based research provides a unique perspective on targeted therapy and the integration of novel treatments into the clinic for the treatment of patients with brain tumors.